Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

Theravance Biopharma, Inc. has just announced the sale of its remaining royalty interest in Trelegy Ellipta to GSK for $225 ...

Andrew Witty, who largely led the U.S. healthcare giant from the U.K., made big bets on Medicare enrollees that backfired.

In a welcome move, GSK ADRGSK saw its Relative Strength Rating rise from 66 to 74 on Monday. Please watch the video at Investors.com - How To Find The Best IPO Stocks Can You Really Time The Stock ...

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Theravance Biopharma shares rose sharply in premarket trading Monday after the biopharmaceutical company said it agreed to sell its remaining royalty interest in sales of the lung-disease treatment ...

(Alliance News) - GSK PLC on Monday announced the US Food & Drug Administration has accepted for review the new drug application for its liver disease treatment, linerixibat.

There’s already overlap in the pharmaceutical industry between the U.K. and Pennsylvania, but details in Trump’s trade deal ...

GSK PLC closed 14.69% below its 52-week high of £17.67, which the company reached on May 31st.